Ordering phenomena in block copolymers have attracted much theoretical and experimental attention. Most work focuses on lamellar mesophases. We have used atomic force microscopy to study cylindrical mesophase formation in thin films of a commercial styrene-butadiene-styrene (SBS) block copolymer. Complex ordering phenomena occur during annealing. We have found that the orientation of polystyrene cylinders depends on the film thickness. For films that are thinner than two repeat distances the orientation is consistently found to be perpendicular to the surface. Parallel orientations can only exist at specific values of the thickness. If the average thickness of the film is not compatible with the repeat distance, the film develops microscopic variations in thickness such that the thicker regions are an integer of the repeat distance. In the thinner regions, the cylinders orient perpendicular to the surface.
Epidermal growth factor receptor (EGF-R) overexpression is common in a large number of solid tumors and represents a negative prognostic indicator. Overexpression of EGF-R is strongly tumor associated, and this tyrosine kinase type receptor is considered an attractive target for Ab therapy. In this study, we describe the evaluation of mAb 2F8, a high avidity human mAb (IgG1κ) directed against EGF-R, developed using human Ig transgenic mice. mAb 2F8 effectively blocked binding of EGF and TGF-α to the EGF-R. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R-overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Ex vivo analysis of the EGF-R status in tumor xenografts in 2F8-treated mice revealed that there are two therapeutic mechanisms. First, blocking of EGF-R signaling, which is most effective at complete receptor saturation and therefore requires a relatively high Ab dose. Second, at very low 2F8 receptor occupancy, we observed potent antitumor effects in mice, which are likely based on the engagement of immune effector mechanisms, in particular ADCC. Taken together, our findings indicate that ADCC represents an important effector mechanism of this Ab, which is effective at relatively low dose.
The Hox gene products are DNA-binding proteins, containing a homeodomain, which function as a class of master control proteins establishing the body plan in organisms as diverse as Drosophila and vertebrates. Hox proteins have recently been shown to bind cooperatively to DNA with another class ofhomeodomain proteins that include extradenticle, Pbxl, and Pbx2. Hox gene products contain a highly conserved hexapeptide connected by a linker ofvariable length to the homeodomain. We show that the hexapeptide and the linker region are required for cooperativity with Pbxl and Pbx2 proteins. Many of the conserved residues present in the Hoxb-8 hexapeptide are required to modulate the DNA binding of the Pbx proteins. Position of the hexapeptide relative to the homeodomain is important. Although deletions of two and four residues of the linker peptide still show cooperative DNA binding, removal of all six linker residues-strongly reduces cooperativity. In addition, an insertion of 10 residues within the linker peptide signiflcantly lowers cooperative DNA binding. These results show that the hexapeptide and the position of the hexapeptide relative to the homeodomain are important determinants to allow cooperative DNA binding involving Hox and Pbx gene products.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.